Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21479470 | 0.78 | LMNA (0.36) | LMNAEPHX2L3MBTL1ALDH1A1HPGD | |
| SCHEMBL9909954 | 0.77 | KMT2A (0.52) | LMNAMEN1KMT2AL3MBTL1KDM4E | |
| SCHEMBL27902219 | 0.76 | LMNA (0.39) | LMNAEPHX2MEN1KMT2A | |
| SCHEMBL22675438 | 0.76 | LMNA (0.39) | LMNAEPHX2MEN1KMT2A | |
| SCHEMBL26710153 | 0.75 | LMNA (0.38) | LMNAEPHX2MEN1KMT2AALDH1A1 | |
| SCHEMBL13483407 | 0.75 | L3MBTL1 (0.36) | LMNAEPHX2L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL21872070 | 0.73 | LMNA (0.37) | LMNA | |
| SCHEMBL21479468 | 0.73 | LMNA (0.33) | LMNA | |
| SCHEMBL28000925 | 0.73 | EPHX2 (0.39) | LMNAEPHX2MEN1KMT2AKDM4E | |
| SCHEMBL15211612 | 0.72 | LMNA (0.33) | LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582712-B1 | Alpha-olefins polymerization catalyst | FORMOSA PLASTICS CORPORATION, U.S.A. (US) | 2009-09-01 | — | — | US | claimed |
| US-11136315-B2 | CXCR2 antagonist | MEDSHINE DISCOVERY INC. (CN) | 2021-10-05 | — | — | US | disclosed |
| US-20200339549-A1 | CXCR2 ANTAGONIST | Shenzhen Optimum Biological Technology Co., Ltd (CN) | 2020-10-29 | — | — | US | disclosed |
| US-7582712-B1 | Alpha-olefins polymerization catalyst | FORMOSA PLASTICS CORPORATION, U.S.A. (US) | 2009-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136315-B2 | CXCR2 antagonist | CXCR2, CXCR3, CXCR1 | LMNA 4876/4885EPHX2 110/4885MEN1 4808/4885 |
| US-20200339549-A1 | CXCR2 ANTAGONIST | CXCR2, CXCR3, CXCR1 | LMNA 4876/4885EPHX2 110/4885MEN1 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.